We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Corcept Therapeutics Incorporated (CORT) - free report >>
Sandstorm Gold Ltd (SAND) - free report >>
Y-mAbs Therapeutics, Inc. (YMAB) - free report >>
Image: Shutterstock
New Strong Buy Stocks for April 17th
Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:
Byrna Technologies Inc. (BYRN - Free Report) : This non-lethal defense technology companyhas seen the Zacks Consensus Estimate for its current year earnings increasing 157.1% over the last 60 days.
Byrna Technologies Inc. Price and Consensus
Byrna Technologies Inc. price-consensus-chart | Byrna Technologies Inc. Quote
Y-mAbs Therapeutics, Inc. (YMAB - Free Report) : This commercial-stage biopharmaceutical company has seen the Zacks Consensus Estimate for its current year earnings increasing 42.7% over the last 60 days.
Y-mAbs Therapeutics, Inc. Price and Consensus
Y-mAbs Therapeutics, Inc. price-consensus-chart | Y-mAbs Therapeutics, Inc. Quote
Sandstorm Gold Ltd. (SAND - Free Report) : This gold royalty company has seen the Zacks Consensus Estimate for its current year earnings increasing 16.7% over the last 60 days.
Sandstorm Gold Ltd Price and Consensus
Sandstorm Gold Ltd price-consensus-chart | Sandstorm Gold Ltd Quote
Corcept Therapeutics Incorporated (CORT - Free Report) : This pharmaceutical company has seen the Zacks Consensus Estimate for its current year earnings increasing 27.8% over the last 60 days.
Corcept Therapeutics Incorporated Price and Consensus
Corcept Therapeutics Incorporated price-consensus-chart | Corcept Therapeutics Incorporated Quote
Enveric Biosciences, Inc. (ENVB - Free Report) : This biotechnology company has seen the Zacks Consensus Estimate for its next year earnings increasing 25.6% over the last 60 days.
Enveric Biosciences, Inc. Price and Consensus
Enveric Biosciences, Inc. price-consensus-chart | Enveric Biosciences, Inc. Quote
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.